Species differences in oxidative metabolism of regorafenib

• Published in: Xenobiotica Vol. 51; no. 12; pp. 1400 - 1407
• Main Authors: Kojima, Ayaka, Sogabe, Ayuka, Nadai, Masayuki, Katoh, Miki
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.12.2021
• Subjects: Animals; kinetic analysis; Kinetics; liver; Mice; Microsomes - metabolism; Microsomes, Liver - metabolism; oxidative metabolism; Oxidative Stress; Phenylurea Compounds - metabolism; Pyridines; Rats; Regorafenib; small intestine; species differences; Species Specificity; oxidative metabolism; Regorafenib; species differences; small intestine; liver; kinetic analysis
• ISSN: 0049-8254; 1366-5928; 1366-5928
• DOI: 10.1080/00498254.2022.2028935

Despite the prevalence of laboratory animals such as monkeys, rats, and mice in clinical drug trials, we know little regarding the oxidation of regorafenib in these test subjects. This study aimed to elucidate species differences in the kinetics of regorafenib oxidation into two metabolites: regorafenib N-oxide (M-2) and hydroxyregorafenib (M-3). M-2 formation best fitted the Hill equation and showed positive cooperativity in liver and small intestinal microsomes from all species. For all species, M-2 formation had a higher maximum velocity in microsomes from the liver than the small intestines. Maximum velocity was also higher in microsomes from humans and monkeys than those from rats and mice. M-3 formation was well-fitted to the Hill equation and showed positive cooperativity in all microsomes, except those from rat small intestines, where it exhibited biphasic kinetics. At half the maximum velocity, substrate concentration for M-2 and M-3 formation was lower in microsomes from humans than from other species. Moreover, M-2 was the major metabolite in microsomes from humans, monkeys, and mice, whereas M-2 and M-3 were the major metabolites in rat microsomes. M-2 and M-3 formation involving CYP3A4 and CYP3A5 fitted to the Hill equation. However, M-3 formation involving CYP2J2 fitted to the substrate inhibition model. Our study confirmed species differences in regorafenib oxidative metabolism.